

23 Oct 2019 |

# Podcast: Woodford's UK Biotech Fallout, Rare Disease Deals and Brexit

*The Low-Down On Big Biopharma Stories*

by **Kevin Grogan**

Scrip's Kevin Grogan and Andrew McConaghie try out the padded cell/recording studio at Informa HQ in London, giving their take on three hot topics from biopharma and healthcare.

A pilot edition podcast from Scrip's Kevin Grogan and Andrew McConaghie, with a special focus on developments in UK and European biopharma and healthcare.

Scrip Podcast

Pilot episode

[Click here to explore this interactive content online](#) 

Woodford's biotech fallout, rare disease deals, Brexit

Covering the fall of former star fund manager Neil Woodford, analysis of a recent spate of big licensing deals in the rare disease space, plus insights on what Brexit will mean for the UK life

sciences sector in the long term.

Please give us feedback on this pilot episode – any comments on guests to invite or topics to cover gratefully received. Email [andrew.mcconaghie@informa.com](mailto:andrew.mcconaghie@informa.com) [kevin.grogan@informa.com](mailto:kevin.grogan@informa.com)